Novavax Presents New Data From Non-Human Primate Ebola Challenge at the 7th International Symposium on Filoviruses
March 28 2015 - 09:37AM
GAITHERSBURG, Md., March 28, 2015 (GLOBE NEWSWIRE)
-- Novavax, Inc. (Nasdaq:NVAX), a
clinical-stage vaccine company focused on the discovery,
development and commercialization of recombinant nanoparticle
vaccines and adjuvants, today announced Gale Smith, Ph.D., Vice
President, Vaccine Development, will present, "Recombinant
EBOV/Makona Glycoprotein (GP) Nanoparticle Vaccine Produced in Sf9
Insect Cells," at the 7th
International Symposium on Filoviruses, Saturday, March 28, 2015 at
10:15 a.m. at the Washington Marriott Metro Center in Washington,
D.C.
As part of his talk, Dr. Smith will present new
data from a second non-human primate (NHP) study which was
conducted by the National Institutes of Health, National Institute
of Allergy and Infectious Diseases, Division of Microbiology and
Infectious Diseases (NIH-NIAID-DMID). In that study, animals
received two injections of a 5µg dose of Novavax' Ebola GP Vaccine
together with its proprietary Matrix-M adjuvant and were then
challenged with a lethal dose of the Ebola virus. Similar to the
previous NHP study, the challenge was lethal for the control
animals, whereas the animals immunized with Novavax' EBOV GP
Vaccine remain healthy 18 days post challenge.
"This data provides significant, independent
confirmation that our Ebola GP Vaccine is safe and effective in
providing protection in NHP models," said Dr. Smith. "Our vaccine
is the first subunit Ebola GP-based vaccine to provide protection
in non-human primates and this confirmatory data strongly supports
the advancement of this program. Importantly, although we developed
our Ebola GP Vaccine from the Makona strain, which is the strain
responsible for the recent Ebola epidemic in West Africa, these
primates were challenged with the Kikwit strain of Ebola, which
suggests that our vaccine candidate may be protective across
different variants of the virus."
Novavax is currently conducting a Phase 1 clinical
trial of its Ebola GP Vaccine in healthy subjects. It expects
top-line data from this trial in mid-2015.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a
clinical-stage vaccine company committed to delivering novel
products to prevent a broad range of infectious diseases. Our
recombinant nanoparticles and Matrix-M(TM) adjuvant technology are
the foundation for groundbreaking innovation that improves global
health through safe and effective vaccines. Additional information
about Novavax is available on the company's website,
www.novavax.com.
Forward-Looking
Statements
Statements contained in this
release, including those relating to the closing of the offering,
and those statements using words such as "expects" and "intends"
are forward-looking statements that involve a number of risks and
uncertainties that could cause actual results to differ materially
from those in the forward-looking statements. These risks and
uncertainties include, but are not limited to: the possible adverse
impact on the market price of our shares of common stock due to the
dilutive effect of the securities to be sold in the offering; our
planned use of the proceeds from this offering; capital market
risks; our ability to raise additional capital when needed; and
other risk factors identified from time to time in the reports we
file with Securities and Exchange Commission (SEC),
including our Annual Report on Form 10-K, Quarterly Reports on Form
10-Q, and Current Reports on Form 8-K, which are available at
www.sec.gov. We caution investors not to place
considerable reliance on the forward-looking statements contained
in this press release. You are encouraged to read our filings with
the SEC, available at sec.gov, for a discussion of these and
other risks and uncertainties. The forward-looking statements in
this press release speak only as of the date of this document, and
we undertake no obligation to update or revise any of the
statements. Our business is subject to substantial risks and
uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration
to these risks and uncertainties.
CONTACT: Novavax, Inc.
Barclay A.
Phillips
SVP, Chief
Financial Officer and Treasurer
Andrea N. Flynn,
Ph.D.
Senior Manager,
Investor Relations
ir@novavax.com
240-268-2000
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#1907151
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024